Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis.

Passiglia F, Rizzo S, Maio MD, Galvano A, Badalamenti G, Listì A, Gulotta L, Castiglia M, Bazan V, Russo A, Fulfaro F.

Sci Rep. 2018 Sep 6;8(1):13379. doi: 10.1038/s41598-018-30780-4.

2.

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.

Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA.

Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. eCollection 2018.

3.

A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.

Peri M, Botteri E, Pisa E, De Marinis F, Ungaro A, Spada F, Grana CM, Gasparri R, Spaggiari L, Romentz N, Badalamenti G, Russo A, Fazio N.

J Thorac Dis. 2018 Jul;10(7):3928-3939. doi: 10.21037/jtd.2018.06.78.

4.

Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives.

Badalamenti G, Messina C, De Luca I, Musso E, Casarin A, Incorvaia L.

Radiol Med. 2018 Apr 4. doi: 10.1007/s11547-018-0883-6. [Epub ahead of print]

PMID:
29619613
5.

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.

Vincenzi B, Badalamenti G, Armento G, Silletta M, Spalato Ceruso M, Catania G, Napolitano A, Maltese G, Valeri S, Incorvaia L, Santini D, Tonini G.

Oncology. 2018;95(1):1-7. doi: 10.1159/000487266. Epub 2018 Mar 6.

PMID:
29510410
6.

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA.

Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19.

7.

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, Vincenzi B, Calò V, Iovanna JL, Bazan V, Russo A.

Cell Immunol. 2018 Jan 30. pii: S0008-8749(18)30014-5. doi: 10.1016/j.cellimm.2018.01.013. [Epub ahead of print] Review.

PMID:
29395859
8.

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconicini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F.

Pancreatology. 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12.

PMID:
29361429
9.

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.

Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G.

Crit Rev Oncol Hematol. 2017 Oct;118:1-6. doi: 10.1016/j.critrevonc.2017.06.006. Epub 2017 Jul 15. Review.

PMID:
28917265
10.

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.

Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G.

Br J Cancer. 2017 Jul 25;117(3):340-346. doi: 10.1038/bjc.2017.187. Epub 2017 Jun 22.

11.

Symptomatic Deep Femoral Artery Pseudoaneurysm Endovascular Exclusion. Case Report and Literature Review.

Pecoraro F, Dinoto E, Bracale UM, Badalamenti G, Farina A, Bajardi G.

Ann Vasc Surg. 2017 Jul;42:303.e5-303.e9. doi: 10.1016/j.avsg.2016.11.026. Epub 2017 Apr 5. Review.

PMID:
28390919
12.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
13.

Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.

Di Lisi D, Madonna R, Zito C, Bronte E, Badalamenti G, Parrella P, Monte I, Tocchetti CG, Russo A, Novo G.

Int J Cardiol. 2017 Jan 15;227:11-17. doi: 10.1016/j.ijcard.2016.11.174. Epub 2016 Nov 9. Review.

PMID:
27866063
14.

Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report.

Leto G, Incorvaia L, Flandina C, Ancona C, Fulfaro F, Crescimanno M, Sepporta MV, Badalamenti G.

Cancer Invest. 2016 Oct 20;34(9):415-423. Epub 2016 Sep 16.

PMID:
27636861
15.

Cinical outcomes of Endurant II stent-graft for infrarenal aortic aneurysm repair: comparison of on-label versus off-label use.

Pecoraro F, Corte G, Dinoto E, Badalamenti G, Bruno S, Bajardi G.

Diagn Interv Radiol. 2016 Sep-Oct;22(5):450-4. doi: 10.5152/dir.2016.15418.

16.

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G.

Sci Rep. 2016 Apr 15;6:22205. doi: 10.1038/srep22205. No abstract available.

17.

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma.

Incorvaia L, Bronte G, Bazan V, Badalamenti G, Rizzo S, Pantuso G, Natoli C, Russo A.

Oncotarget. 2016 Apr 19;7(16):21259-71. doi: 10.18632/oncotarget.7267. Review.

18.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G.

Sci Rep. 2015 Dec 22;5:18670. doi: 10.1038/srep18670. Erratum in: Sci Rep. 2016;6:22205. multiple author names corrected.

19.

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.

Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G.

Oncotarget. 2016 Oct 25;7(43):69412-69419. doi: 10.18632/oncotarget.5136.

20.

Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.

Vincenzi B, Stumbo L, Maltese G, Cerbone L, Spalato Ceruso M, Badalamenti G, Santini D, Tonini G, Frezza AM, De Lisi D, Silletta M.

Sci Rep. 2015 Aug 3;5:12077. doi: 10.1038/srep12077.

Supplemental Content

Loading ...
Support Center